Shares in Mylan (NSDQ:MYL) rose today after the EpiPen-maker met expectations on Wall Street with its 4th quarter results.
The Canonsburg, Pa.-based company posted profits of $417.5 million, or $1.57 per share, on sales of $3.27 billion for the 3 months ended Dec. 31, for bottom-line growth of 114.5% on sales growth of 31.3% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were $1.57, ahead of consensus on The Street, where analysts were looking for sales of $2.37 billion.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan posts Street-beating Q4 earnings appeared first on MassDevice.
from MassDevice http://ift.tt/2m8CDqJ
Cap comentari:
Publica un comentari a l'entrada